Supernus Pharmaceuticals
SUPN
SUPN
246 hedge funds and large institutions have $1.44B invested in Supernus Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 90 increasing their positions, 90 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
246
Holders Change
+13
Holders Change %
+5.58%
% of All Funds
6.13%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.15%
New
40
Increased
90
Reduced
90
Closed
19
Calls
$10.5M
Puts
$9.47M
Net Calls
+$1.05M
Net Calls Change
+$2.23M
Top Buyers
| 1 |
BlackRock
New York
|
$210M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
$16.4M |
| 3 |
Millennium Management
New York
|
$17.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$18.3M |
| 5 |
Axa
Paris,
France
|
$6.52M |
Top Sellers
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
$5.98M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
$0 |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
$19.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
$51.9M |
| 5 |
Morgan Stanley
New York
|
$10.9M |
